Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $32 at Stifel on "Bear Biotech Market", "Remain Believers in Acute HAE Opportunity, KVD824 Looking Most Underappreciated"
Tweet Send to a Friend
Stifel analyst Paul Matteis lowered the price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) to $32.00 (from $54.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
